Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer

Conclusion: Our data demonstrate that an oHSV encoding a full-length human IgG1 anti-CD47 mAb, when used as a single agent or combined with another agent, is a promising approach for improving ovarian cancer treatment via enhancing innate immunity, as well as performing its known oncolytic function and modulation of immune cells.PMID:34645647 | DOI:10.1158/1078-0432.CCR-21-1248

Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Lei Tian Bo Xu Kun-Yu Teng Mihae Song Zheng Zhu Yuqing Chen Jing Wang Jianying Zhang Mingye Feng Balveen Kaur Lorna Rodriguez-Rodriguez Michael A Caligiuri Jianhua Yu Source Type: research